If you have been diagnosed with chronic fatigue syndrome (aka myalgic encephalomyelitis or systemic exertion intolerance disease) or have debilitating and chronic fatigue, you may be eligible to participate in a treatment clinical trial that we are conducting at UAB in Birmingham, Alabama.
Benefits of the study:
- Participants get to try a new medication that may reduce their symptoms.
- Participants completing the study will receive $425.
- Participants will receive some blood tests and will be informed of the results.
- Once a month, while the study is being conducted, participants must be able to come to a 2-hour visit at the University of Alabama in Birmingham.
- Participants must be able to participate for a period of 7 months.
- Participants must have been diagnosed with CFS (aka ME/SEID) or have experienced chronic, debilitating fatigue during the previous 12 months.
- Participants must not be on an opioid treatment for pain.
- Participants must be women who are 18-65 in age.
There may be other participant requirements not mentioned above.
About the Study:
The primary purpose of this study is to determine whether low-dose naltrexone affects the immune system function and symptoms of people who have chronic fatigue or chronic fatigue syndrome. The study is expected to last 7 months. In addition to the monthly visits to UAB, participants will need to take the drug or placebo daily and report symptoms on a electronic tablet we provide. This is a double-blind, placebo-controlled study. All participants will be given LDN treatment at some point of their study participation.
If you are interested in participating in any of our other studies, please fill out this screener.